On BeiGene’s very first live earnings call, CEO and co-founder John Oyler on Thursday described a “once-in-a-lifetime ...

Investment analysts at Zacks Research dropped their Q3 2025 earnings per share (EPS) estimates for shares of AstraZeneca in a report issued on Thursday, February 27th. Zacks Research analyst R.

Eli Lilly and Company LLY announced that the European Medicines Agency's Committee for Medicinal Products for Human Use ...

AstraZeneca AZN stock has risen 8.6% in the past month, mainly due to mixed fourth-quarter results and a positive update from ...

New York State Common Retirement Fund grew its position in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 7.4% during the 4th ...

who are ineligible for autologous hematopoietic stem cell transplantation (HSCT), according to a news release from AstraZeneca. Importantly, Calquence is now the first and only Bruton tyrosine kinase ...

Learn more about whether AstraZeneca PLC or Intra-Cellular Therapies, Inc. is a better investment based on AAII's A+ Investor ...

AstraZeneca's Calquence has hit the mark in the phase 3 AMPLIFY trial in chronic lymphocytic leukaemia (CLL), a study that chief executive Pascal Soriot recently said could be a "blockbuster ...

AstraZeneca’s fast-growing BTK inhibitor Calquence is already challenging class leader Imbruvica from Johnson & Johnson/AbbVie in the treatment of chronic lymphocytic leukaemia (CLL).

AstraZeneca Q4 revenue rose 18% to $14.89 ... Tagrisso sales were up 20% to $1.70 billion (21% at CER), Calquence sales increased 20% to $808 million, Lynparza sales increased 46% (+47%) to ...